S-ClassAbout S-Class
H
HOWLAI Stock Diagnostic Report
Werewolf Therapeutics GAAP EPS of $0.08 beats by $0.40, revenue of $21M
Werewolf Therapeutics reported GAAP earnings per share (EPS) and revenue that significantly exceeded market expectations.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$0.5Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support0.45
Near-Term Resistance0.55
02
FUNDAMENTALS
Financial & Fundamental Analysis
GAAP EPS of $0.08 exceeded expectations by $0.40, achieving a return to profitability and an earnings surprise, with quarterly revenue recorded at $21 million.
03
TECHNICAL VIEW
Technical Position & Response Criteria
At the current price of $0.50, it is necessary to monitor movements between the short-term support and resistance levels and respond accordingly.
Support0.45
Resistance0.55
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
A short-term momentum was generated through the earnings announcement; however, specific self-execution plans and timelines for future production or clinical activities controlled by the company are not confirmed in the text.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-07-31)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.